Detalles de la búsqueda
1.
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial).
Ann Surg Oncol
; 31(2): 1207-1216, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38099993
2.
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives.
Curr Opin Obstet Gynecol
; 36(1): 9-17, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170548
3.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052965
4.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36965291
5.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37355448
6.
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience.
Int J Gynecol Cancer
; 33(4): 514-520, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746489
7.
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
Int J Gynecol Cancer
; 33(6): 922-928, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759000
8.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869143
9.
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol
; 167(3): 436-443, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36220670
10.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539744
11.
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Int J Gynecol Cancer
; 31(8): 1175-1178, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34131041
12.
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Int J Gynecol Cancer
; 31(10): 1369-1373, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34607820
13.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990353
14.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33931498
15.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462317
16.
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Gynecol Oncol
; 156(3): 523-529, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31916979
17.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol
; 156(1): 38-44, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31699415
18.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Expert Opin Emerg Drugs
; 25(4): 445-453, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33040627
19.
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Support Care Cancer
; 28(5): 2435-2442, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048043
20.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31029508